A study presented at IDWeek 2026 in Washington, DC, found that children whose pediatricians recommended HPV vaccination at ages 9–10 had more than twice the odds of starting and completing the HPV vaccine series by age 13 compared with those whose pediatricians introduced the vaccine at ages 11–12.
These findings add to growing evidence that earlier HPV vaccination may help improve vaccine series completion rates and provide protection against HPV-related cancers before potential exposure.
For pediatric practices, ensuring patients complete the vaccine series is just as important as initiating it. CPP Buying Group’s 2nd Dose Grant Program helps practices evaluate second-dose immunization rates, access resources to implement strategies that improve vaccine completion, and share successful approaches with other CPP members.
Eligible vaccines include COVID-19, meningococcal ACWY, HPV, and adult hepatitis B (Heplisav-B only).
Read the full Medscape article: Earlier HPV Vaccination Improves Initiation, Completion